Barry D. Quart
2013
In 2013, Barry D. Quart earned a total compensation of $8.3M as Chief Executive Officer at Heron Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $240,637 |
|---|---|
| Option Awards | $7,625,250 |
| Salary | $349,327 |
| Other | $41,000 |
| Total | $8,256,214 |
Quart received $7.6M in option awards, accounting for 92% of the total pay in 2013.
Quart also received $240.6K in non-equity incentive plan, $349.3K in salary and $41K in other compensation.
Rankings
In 2013, Barry D. Quart's compensation ranked 587th out of 12,286 executives tracked by ExecPay. In other words, Quart earned more than 95.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 587 out of 12,286 | 95th |
Division Manufacturing | 182 out of 4,612 | 96th |
Major group Chemicals And Allied Products | 45 out of 1,462 | 97th |
Industry group Drugs | 27 out of 1,156 | 98th |
Industry Pharmaceutical Preparations | 25 out of 890 | 97th |
Source: SEC filing on April 29, 2016.
Quart's colleagues
We found three more compensation records of executives who worked with Barry D. Quart at Heron Therapeutics in 2013.
News
Heron Therapeutics CEO Craig Collard receives $11M in 2023
April 29, 2024
Heron Therapeutics Executive Vice President, Drug Development Kimberly Manhard's 2022 pay falls 22% to $1.4M
May 1, 2023
Heron Therapeutics CEO Barry Quart's 2021 pay rises 2% to $5.4M
April 25, 2022
Heron Therapeutics CEO Barry Quart's 2020 pay slips 9% to $5.3M
April 22, 2021
Heron Therapeutics CEO Barry Quart's 2019 pay slips 2% to $5.9M
April 23, 2020